Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?

Tomkins-Netzer, O, Taylor, SRJ and Lightman, S (2013) Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica, 230 (3). pp. 109-115.

Full text not available from this repository.

Abstract

Treatment of non-infectious uveitis is based primarily on the use of systemic corticosteroids and second-line immunosuppressive drugs. However, their extensive side effect profile, particularly for steroids, has led to the increased use of other immunosuppressive drugs, as sparing capacity agents. Rituximab is an anti-CD20 chimeric antibody, often given as a single course of 2 infusions, resulting in complete depletion of peripheral mature B cells. While it is licensed to treat refractory systemic lymphoma patients, it has also shown promising results in systemic auto-immune diseases, where a single course of treatment is able to achieve long-term clinical remission. Treatment with rituximab has been reported for various ocular conditions, suggesting it may be effective in inducing long-term disease control and other systemic immunosuppressive agents can be reduced or discontinued. When disease relapse occurs, a further course or courses can be given with good results. This review summarizes the current evidence regarding the role of rituximab in treating non-infectious uveitis. © 2013 S. Karger AG, Basel.

Item Type:	Article
Divisions :	Surrey research (other units)
Authors :	Name Email ORCID Tomkins-Netzer, O Taylor, SRJ s.r.taylor@surrey.ac.uk Lightman, S
Date :	1 September 2013
DOI :	10.1159/000351426
Depositing User :	Symplectic Elements
Date Deposited :	17 May 2017 10:41
Last Modified :	24 Jan 2020 19:50
URI:	http://epubs.surrey.ac.uk/id/eprint/828783

Actions (login required)

View Item

Downloads